RRR-a-tocopheryl succinate (a-vitamin E succinate, VES), one of the vitamin E derivatives, can effectively inhibit the proliferation of human prostate cancer cells. However, little is known about its effect on prostate cancer cell invasive ability. Tumor metastasis is a complex process and the extracellular matrix (ECM) is the first barrier that tumor cells encounter. Therefore, we tested the effect of VES on the invasion of different prostate tumor cells, PC-3, DU-145, and LNCaP, through Matrigel, a reconstituted ECM, using an in vitro cell invasion assay. The invasion of PC-3 and DU-145 cells through Matrigel was inhibited by 20 lM VES after treating for 24 h. The condition did not alter cell survival, cell cycle, cell adhesion or cell motility. We further investigated whether the ability of VES to inhibit prostate cancer cell invasiveness was associated with its ability to inhibit the activity of matrix metalloproteinases (MMPs), the key enzymes in the proteolysis of basement membrane during invasion. PC-3 and DU-145 cells that were treated with VES showed a significant reduction in the levels of MMP-9 in the culture medium. In contrast, LNCaP cells, which did not secrete MMP-9, were poorly invasive in Matrigel and were hardly affected by treatment with VES. This is the first report suggesting that VES inhibits human prostate cancer cell invasiveness and the reduction of secreted MMP-9 activity could be one of the contributory factors, which points to the potential use of VES in the prevention and therapy of prostate cancer invasion.
Introduction
Prostate cancer is the most common noncutaneous cancer and the second leading cause of deaths for males, with one in every five men developing invasive cancer. In 2003, an estimated 220 900 men will be diagnosed with this disease (Jemal et al., 2003) . For confined disease of low to moderately differentiated prostate cancer, surgical or radiotherapy techniques are curative in the majority of individuals. However, it is usually fatal once the tumor cells migrate outside the area of the gland (Denmeade and Isaacs, 1997); these patients are estimated to account for 30 200 deaths in 2003 (Jemal et al., 2003) . Cytotoxic chemotherapy is being used to control and treat prostate cancer at this stage, but remains relatively nonselective and highly toxic to normal tissues. Therefore, there is an urgent need for less toxic compounds capable of interfering with one or more steps of the metastatic process.
Tumor metastasis is a complex process in which metastatic cells migrate beyond tissue compartment boundaries and spread into different organs (Jiang et al., 1994) . The extracellular matrix (ECM) is the first barrier that tumor cells encounter during metastasis. It is composed of laminin, collagen IV, heparin sulfate proteoglycan, and entactin (Iwamoto and Sugioka, 1992) . Tumor cells dissolve these components using a variety of matrix-degrading enzymes, including cysteine proteases (e.g. cathepsin D), serine proteases (e.g. plasminogen activator), and matrix metalloproteinases (MMPs). Degradation of ECM is a distinctive feature of invasive cells and has been the target of extensive research in an attempt to develop therapeutic agents that could prove useful in treating cancer metastases. MMPs inhibitor, Marimastat, has been used for patients with aggressive prostate cancer and has shown therapeutic responses encouraging the application of MMPs inhibitors as adjuvant therapeutic agents for prostate cancer (Rasmussen and McCann, 1997) .
Epidemiological studies show that the incidence of prostate cancer is low in the population receiving longterm supplements of vitamin E, which suggests a chemopreventive role for vitamin E (The a-Tocopherol, b-Carotene Cancer Prevention Study Group, 1994) . Many studies have demonstrated that VES, the succinate derivative of RRR-a-tocopherol (a-vitamin E, a-VE), is the most effective form of vitamin E for adjuvant cancer treatment (Prasad et al., 2003) . We previously demonstrated that VES inhibited prostate cancer cell growth through the suppression of the androgen/ androgen receptor pathway as well as the modulation of cell cycle regulatory machinery (Zhang et al., 2002; Ni et al., 2003) . In this study, we evaluated the effect of VES on the in vitro invasion of prostate tumor cells (PC-3, DU-145, and LNCaP) through Matrigel, a reconstituted basement membrane. We further investigated whether the ability of VES to inhibit prostate cancer cell invasiveness is associated with its ability to inhibit the activity of MMPs. We found that VES inhibited the invasion of prostate cancer cells and the anti-invasion effect was associated with the reduction of MMP-9 activity. Our findings support the possibility that VES could be an antimetastatic drug in prostate cancer therapy.
Results

VES inhibits the in vitro invasion of PC-3 prostate cancer cells
Invasion through the ECM is a crucial step in tumor metastasis. Matrigel can be used in vitro as a reconstituted basement membrane that provides a biologically active ECM. Fibroblasts conditioned medium (FCM), which contains known (i.e. fibronectin and collagen) as well as unknown chemotactic factors, can stimulate the penetration of tumor cells. After treatment with 20 mM VES for 24 h, PC-3 cells showed a significant reduction in FCM-stimulated invasiveness through Matrigel, whereas succinate salt treatment had no significant effect ( Figure 1a and b, lanes 2 and 3 vs 1).
Effects of different vitamin E derivatives on the invasion of PC-3 prostate tumor cells through Matrigel
Currently, several chemical versions of vitamin E are available as dietary supplements, including a-VE, VES, and RRR-a-tocopheryl acetate (a-vitamin E acetate, VEA). In addition, these vitamin E derivatives have been used in studies of cancer cell growth inhibition. We compared the effect of VES on prostate cancer cell invasion with that of a-VE and VEA. As shown in Figure 1b , VES was the only agent to inhibit significantly the invasion of PC-3 cells through Matrigel, also suggesting that inhibition of tumor cell invasion was dependent on the intact molecule of VES instead of its components, a-VE and succinate ( Figure 1b , lanes 3 vs 2 and 4).
Effect of VES on the survival of PC-3 prostate cancer cells
To rule out the possibility that VES inhibits prostate cancer cell invasion by affecting cell survival, we performed Trypan blue exclusion assays on prostate cancer cells. Trypan blue is a stain that will only enter across the membrane of dead/nonviable cells. PC-3 cells were treated with 0.1% ethanol, 20 mM succinate, or VES for 24 h at the conditions used in the invasion assay. Cells both suspended in the media and attached to the plates were harvested and exposed to 0.4% Trypan blue. When counted under a light microscope, all cells remained small, round, and refractile. This result revealed that under the conditions we used in the invasion assay, few cells died in the presence of 20 mM VES within 24 h, suggesting that the anti-invasive effect of VES was not due to its inhibiting effect on the survival of prostate cancer cells (Figure 2a ).
Effect of VES on the cell cycle distribution of PC-3 prostate cancer cells
In addition to testing cell survival, we determined whether VES-mediated inhibition of invasion might result from cell cycle distribution changes. PC-3 cells were treated with 0.1% ethanol, 20 mM succinate, or VES for 24 h, and then harvested to examine the cell cycle distribution by flow cytometry. As shown in Figure 2b , 24 h treatment of PC-3 cells with 20 mM succinate or VES demonstrated no alteration in the number of cells distributed in G1, S, or G2 phase, although 48 h or longer treatment with VES resulted in cell cycle arrest in our previous studies (Ni et al., 2003) .
Effect of VES on adhesion and motility of PC-3 prostate cancer cells to Matrigel
Tumor cell adhesion to the ECM is an important step of the invasion process (Terranova et al., 1986) . Therefore, 3) . To study the effects of different vitamin E derivatives on PC-3 cell invasiveness, cells were also treated with 20 mM a-VE or VEA for 24 h (lanes 4 and 5). Data represent the mean7s.d. of at least three independent experiments. Results were statistically significant (*Po0.05) using Student's t-test
Effect of RRR-a-tocopheryl on prostate cells M Zhang et al we examined the effect of VES on the adhesion of PC-3 cells to Matrigel. Figure 2c shows that 20 mM succinate or VES treatment had no significant effect on adhesion of PC-3 cells to Matrigel.
Motility is also one of the important steps in tumor invasion, and serves as a sensitive indicator of nonspecific drug toxicity at the time of the invasion assay (Terranova et al., 1986) . To determine whether the antiinvasive activity of VES was attributable to its effect on cell motility, cellular chemotaxis of PC-3 cells toward FCM was tested using control chambers that were prepared with filters not coated with Matrigel. Our results indicated that treatment with 20 mM succinate or VES did not reduce the ability of prostate tumor cells to cross the filters toward FCM (Figure 2d ). Together, results from Figure 2 suggested that treatment with 20 mM VES for 24 h inhibited PC-3 cell invasiveness without affecting cell survival, cell cycle distribution, adhesion, or motility.
VES reduces the secretion of MMP-9 from PC-3 prostate cancer cells
To test whether the anti-invasion effect of VES is correlated with a decreased ability of prostate cancer cells to produce MMPs, we examined the VES effect on Effect of RRR-a-tocopheryl on prostate cells M Zhang et al the MMPs activity in PC-3 prostate cancer cells. We first investigated MMPs activity in total protein extractions of cell lysates. Gelatin-digested bands were barely detectable on the zymogram, despite loading 100 mg of protein per lane (data not shown). Next, an analysis of MMP activity secreted from cells was carried out by loading 30 ml of 20-fold concentrated conditioned media on zymogels. As shown in Figure 3a , conditioned medium collected from PC-3 cells that was treated with 20 mM VES showed a significantly decreased amount of secreted MMP-9 activity when compared with ethanolor succinate-treated cells. In this particular gel, VES seemed to cause a slight reduction in the secreted MMP-2 activity, but it was difficult to get significant results due to the low activity of secreted MMP-2 from PC-3 cells (Li and Sarkar, 2002) .
To further quantify the effect of VES on the secretion of MMP-9 from PC-3 cells, we performed MMP-9 enzyme-linked immunoadsorbent assay (ELISA). Cells were seeded and treated at the conditions we used in the invasion assay. As shown in Figure 3b , a decrease in the concentration of MMP-9 was observed after 24 h treatment of 20 mM VES in PC-3 cells. These results support the zymographic data mentioned above.
Effect of VES on MMP-9 mRNA levels in PC-3 prostate cancer cells
To determine whether reduced MMP-9 activity in VEStreated cells correlated with a lower MMP-9 gene expression at the mRNA level, real-time polymerase chain reaction (PCR) analyses were applied. MMP-9 mRNA expression in cells treated with VES was compared with those treated with ethanol or succinate. The results from the real-time PCR analysis showed that 24 h treatment with 20 mM VES did not significantly alter the mRNA expression of MMP-9 in PC-3 cells (Figure 3c ). Together, our data indicated that VES treatment reduced MMP-9 activity by mechanisms other than inhibition of MMP-9 gene expression at the mRNA level.
Effects of different agents on the secretion of MMP-9 from PC-3 prostate cancer cells
To determine whether the inhibitory effect of VES on MMP-9 activity is independent of its antiproliferative effect, or whether any agents that inhibit the cell proliferation can reduce MMPs activity, we compared the effects of VES, quercetin, and silibinin on the secretion of MMP-9 from PC-3 cells. In PC-3 cells, Figure 3 Effect of VES on the MMP-9 secretion and mRNA levels of PC-3 prostate tumor cells. (a) MMP-9 zymography. PC-3 cells were treated with 0.1% ethanol (control), 20 mM succinate, or VES in serum-free media for 24 h. Conditioned media, normalized to cell number, were collected, 20-fold concentrated, and subjected to gelatin zymography. The blot shown is a representative of at least four independent experiments. (b) MMP-9 ELISA. PC-3 cells were seeded and treated in 24-well plates at the conditions used in the invasion assay. After 24 h incubation, the levels of MMP-9 present in the conditioned medium was measured by ELISA using MMP-9 BIOTRAKTM assay kit (Amersham Pharmacia Bioteh). The results are representative of at least three independent experiments. Results were statistically significant (*Po0.05) using Student's t-test. (c) Real-time PCR quantification of MMP-9 mRNA. PC-3 cells were treated with different agents in serum-free media. After 24 h, the MMP-9 mRNA levels were quantified by real-time PCR assay. MMP-9 mRNA levels were normalized with b-actin and expressed as % of control. The data presented are the means7s.d. from three separate experiments, each triplicated Effect of RRR-a-tocopheryl on prostate cells M Zhang et al treatment with 1 nM quercetin or 2 mM silibinin results in similar antiproliferative effects as 20 mM VES treatment (Kampa et al., 2000; Zi et al., 2000) ; however, our result suggested that only VES could reduce the activity of secreted MMP-9 (Figure 4 ). We used 50 mM genistein as a positive control, as it was reported that 50 mM genistein significantly decreased the activity of MMP-9 secreted from PC-3 cells (Li and Sarkar, 2002) . Together, our results indicated that VES effectively and selectively inhibited the MMP-9 activity, and this effect was independent of its antiproliferative effect.
Effect of VES on the activity of tissue inhibitors of matrix metalloproteinase (TIMPs) secreted from PC-3 prostate cancer cells
The TIMPs have been recognized as the 'balancing' factors in MMPs-induced invasion and metastasis. TIMPs are 21-28 kDa size proteins that specifically block MMPs activity by binding to the highly conserved zinc-binding site of active MMPs (Coussens et al., 2002) . As we have observed reduced MMP-9 activity, we tested the TIMPs by reverse zymography. Reverse zymography of conditioned media that were collected from control and treated PC-3 cells indicated that PC-3 cells secreted both TIMP-1 and TIMP-2; however, VES did not affect the ability of PC-3 cells to secrete TIMP-1 or TIMP-2 ( Figure 5 ).
Effects of VES on the cell invasiveness and MMP-9 secretion of other prostate tumor cells
In addition to studies on PC-3 cells, we also tested the effects of VES on the cell invasiveness and MMP-9 secretion with other metastatic prostate tumor cell lines, DU-145 and LNCaP. As shown in Figure 6a , DU-145 cells had a lower invasion rate through Matrigel as compared to PC-3 cells. After treatment with 20 mM VES for 24 h, decreased invasiveness was also noted with DU-145 cells (Figure 6a, lanes 4 vs 3) . LNCaP cells were poorly invasive in Matrigel and treatment with VES showed little effect (Figure 6a, lanes 6 vs 5) . Zymography showed that treatment with 20 mM VES for 24 h reduced MMP-9 activity in DU-145 cells. LNCaP cells did not secrete MMP-9 (Figure 6b) . Results from ELISA were in agreement with those found with zymography. The concentration of MMP-9 in conditioned media of DU-145 cells decreased after 24 h treatment of 20 mM VES (Figure 6c, lanes 2 vs 1) , but again the MMP-9 levels in conditioned media of LNCaP cells were undetectable (Figure 6c, lanes 3 and 4) . Together, our results indicate that VES not only inhibits cell proliferation but also inhibits cell invasiveness in different human prostate cancer cell lines. This finding may broaden the potential clinical application of VES.
Discussion
The principal clinical problem in prostate cancer is metastatic disease. Although it is first responsive to antiandrogen therapy, prostate cancer eventually recurs, metastasizes, and becomes fatal. VES is known to inhibit the proliferation of prostate cancer cells; however, little is known about the effect of VES on prostate cancer invasion and metastasis. Since the dissolution of basement membrane components is a critical step in the multistep cascade that leads to metastasis, we sought to investigate the effects of VES on the invasiveness of human prostate cancer cells through Matrigel, a reconstituted ECM. In this study, we showed that the invasion of PC-3 and DU-145 cells through Matrigel was inhibited by 24 h treatment with 20 mM VES. This is the first study to demonstrate the potential role of VES in human prostate cancer metastases. We sought to perform the assays in such a way that cell proliferation would not be a confounding variable. Our previous studies have demonstrated an antiproliferative effect and cell cycle arrest effect of VES in human prostate cancer cells with 48 h or longer treatment (Zhang et al., 2002; Ni et al., 2003) . Therefore, we used 24 h conditions for Trypan blue exclusion assays and flow cytometric analyses to determine whether the anti-invasive effects we observed could be accounted for through either alteration of cell viability or modulation of the cell cycle. Figure 4 The effects of different agents on the secretion of MMP-9 from PC-3 prostate tumor cells. Cells were treated with 0.1% ethanol (control), 20 mM VES, 1 nM quercetin, 2 mM silibinin, or 50 mM genistein in serum-free media for 24 h. Conditioned media, normalized to cell number, were collected, 20-fold concentrated, and subjected to gelatin zymography. The blot shown is a representative of at least three independent experiments Figure 5 Effect of VES on the secretion of TIMPs from PC-3 prostate tumor cells. Cells that were treated with 0.1% ethanol (control), 20 mM succinate, or VES were incubated in serum-free media for 24 h. The media, normalized to cell number, were collected, 20-fold concentrated, and analysed by reverse zymography. The blot shown is a representative of at least three independent experiments
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We found that VES did not affect cell viability or the cell cycle parameters in prostate cancer cells under 24 h treatment, an experimental condition allowing the observation of the invasiveness inhibition before the elicitation of antiproliferation effect. Thus, the antiinvasive effect of VES was not attributable to cell death or cell cycle arrest, but rather involved specific reduction of the ability of tumor cells to invade through Matrigel. Furthermore, this reduced invasion was not associated with decreased cell motility, or adhesion to ECM. VES as an agent that can modify the invasive phenotype has obvious potential as an antimetastatic drug. Barnett et al. demonstrated that 2 weeks of treatment with VES inhibited colon cancer growth as well as liver metastases in xenografted nude mice. However, it is still uncertain whether VES inhibition of metastases is secondary to its effect on primary tumor growth in their model (Barnett et al., 2002) . Our data demonstrated the direct inhibitive effect of VES on the metastases of prostate cancer cells. Our studies also found that VES, when compared to both a-VE and succinate, was the only agent to inhibit human prostate cancer cell invasiveness. Thus, delivery of the intact molecule of VES to the tumor is necessary. However, oral application of VES leads to quantitative intestinal hydrolysis yielding the free succinate and a-VE (Cheeseman et al., 1995) . If VES could be considered as a therapeutic agent, hydrolysis of the drug has to be avoided by application of either nonhydrolysable VES derivatives or other than oral routes. Esters of a-VE, particularly VES and VEA, are often used as vitamin E supplements due to their reduced sensitivity towards oxidation as compared to free a-VE. In our study, VES was a more potent inhibitor of tumor cell invasiveness than other types of vitamin E. Therefore, the antiinvasive properties of VES appear to be unique to this particular tocopherol derivative. VES is worth noting not only for its anti-invasive effect on prostate cancer cells but also for its lack of toxicity toward normal cells and tissues. Weber et al. reported that there is no toxicity or side effects in mice after the injection of 50 ml of 100 mM VES, which increases VES concentration in several organs to as high as 500 nmol/g, a concentration range of 500-800 mM (Weber et al., 2002) . Furthermore, VES has demonstrated an excellent safety and tolerability profile in clinical trials utilizing high doses of VES in children with vitamin E deficiency (Sokol et al., 1993) .
MMPs are proteases that are thought to play a central role in tumor invasion and metastasis by degrading the matrix. Several studies have shown an association of increased production of MMPs with malignant progression of prostate cancer. Prostate cancer cells secrete high levels of MMPs and low levels of TIMPs, thus creating an excess balance of MMPs (Lokeshwar et al., 1993) . Established prostate cancer cell lines that express high levels of MMPs frequently metastasize to the bone and the lungs (Stephenson et al., 1992) . Drugs such as paclitaxel and alendronate that inhibit MMPs secretion reduce bone metastases of xenografted prostate tumors (Stearns and Wang, 1996) . So far, one clinical study has zymography. DU-145 and LNCaP cells were treated with 0.1% ethanol or 20 mM VES in serum-free media for 24 h. Conditioned media, normalized to cell number, were collected, 20-fold concentrated, and subjected to gelatin zymography. The blot shown is a representative of at least three independent experiments. (c) MMP-9 ELISA. DU-145 and LNCaP cells were seeded and treated in 24-well plates at the conditions used in the invasion assay. After 24 h incubation, the levels of MMP-9 present in the conditioned medium of prostate cancer cells was measured by ELISA using MMP-9 BIOTRAKTM assay kit (Amersham Pharmacia Bioteh). Data represent the mean7s.d. of at least three independent experiments. Results were statistically significant (*Po0.05) using Student's t-test
Effect of RRR-a-tocopheryl on prostate cells M Zhang et al reported using the MMP inhibitor, Marimastat, against prostate cancer (Rasmussen and McCann, 1997) . The therapeutic response was encouraging, as measured by a decrease in the rate of rise of serum prostate-specific antigen levels, suggesting that MMPs inhibitors could be considered as adjuvant therapeutic agents for prostate cancer patients. Our study suggests that VES is a new candidate among such therapeutic agents for prostate cancer.
Secretion of MMP-9 from prostate cancer cells was inhibited by 20 mM VES with 24 h treatment. The condition did not decrease cell survival or alter the cell cycle. This indicated that the inhibitory effect of VES on MMP-9 secretion was independent of its antiproliferative effect. This was further strengthened by the lack of effect of 1 nM quercetin and 2 mM silibinin on MMP-9 activity, although they had similar antiproliferative effects when compared with 20 mM VES during 2 or 5 days of treatment (Kampa et al., 2000; Zi et al., 2000) . Drugs that inhibit the metastatic process are not likely to discriminate between androgen-dependent and androgen-independent prostate tumor cells. Thus, VES is one of the drugs with such potential. MMP activity is regulated by multiple mechanisms, including gene transcription, secretion, activation, inhibition by TIMPs, and glycosylation (Van den Steen et al., 2002) . Our data indicated that VES neither affected the ability of PC-3 cells to secrete TIMP-1 or TIMP-2 into the medium nor altered the mRNA expression of MMP-9 in PC-3 cells. However, it is not clear whether and how VES is able to affect other mechanisms, such as activation, glycosylation, etc. In addition, other matrix-degrading enzymes, including cysteine proteases (e.g. cathepsin D) and serine proteases (e.g. plasminogen activator), could be the potential targets of VES and involved in the mechanisms for the inhibition of invasiveness by VES treatment. These mechanisms need to be studied in the near future. Although the detailed inhibitory mechanism is not yet determined, our results clearly indicate that the anti-invasive effect of VES is associated with the inhibition of enzymatic degradative processes of tumor invasion.
In summary, we report that VES significantly inhibits the invasion of human prostate cancer cells. The antiinvasion effect is correlated with a decreased ability of prostate cancer cells to produce active matrix-degrading proteases. We conclude that the antitumor actions of VES in human prostate cancer involve, in part, the inhibition of cell invasiveness. In addition to its inhibition effect on prostate cancer cell proliferation, our findings point to the potential use of VES in the prevention and therapy of prostate cancer invasion.
Materials and methods
Cell culture conditions
PC-3, DU-145, and LNCaP prostate tumor cells were obtained from the American Type Culture Collection (Manassas, VA, USA). Human prostate fibroblasts were primarily cultured from normal prostate tissues adjacent to cancer counterpart. PC-3, LNCaP, and human prostate fibroblasts were maintained in phenol red-free RPMI 1640 medium (Gibco, Carlsbad, CA, USA), while DU-145 in Dulbecco's modified Eagle's medium (DMEM) (Gibco, Carlsbad, CA, USA), supplemented with 10% fetal bovine serum and 100 U/ml penicillin-100 mg/ml streptomycin in a humidified atmosphere of 5% CO 2 at 371C. Cells were fed with fresh media every 3rd day and were passaged routinely at a confluence of B80%.
Chemicals
VES, a-VE, VEA, succinate, quercetin, silibinin, and genistein were purchased from Sigma (St Louis, MO, USA). Gelatin was obtained from Bio-Rad Laboratories (Hercules, CA, USA) and Pro-gelatinese B from Chemicon International Inc. (Temecula, CA, USA).
Cell invasion assay
Tumor cell invasiveness was determined using BioCoat Matrigel Invasion Chambers (BD Biosciences, Bedford, MA, USA). Briefly, cells were suspended in serum-free media containing different agents. Cells (2.5 Â 10 5 in 0.5 ml medium) were added to the upper chamber. Human FCM, obtained by incubation of the cells for 24 h in serum-free medium, was used as a source of chemoattractants and was placed in the lower compartment of the chamber. The chambers were incubated at 371C in a humidified 5% CO 2 atmosphere for 24 h. At the end of the incubation period, the Matrigel and the cells on the upper surface of the filter were completely removed by wiping with a moist cotton swab. Cells that had invaded the Matrigel and had migrated through the filter and adhered to its lower surface were fixed with 100% methanol and stained with 1% Toluidine Blue in 1% borax. Cells from various areas of the lower surface were counted under a Â 100 microscope (Albini et al., 1987) . Invasiveness was assayed in triplicate for each condition, and in at least three independent experiments.
Trypan blue exclusion assay
Cells were suspended in serum-free media containing 0.1% ethanol, 20 mM succinate, or VES. Cells were seeded in 24-well plates (2.5 Â 10 5 in 0.5 ml medium/well). The plates were incubated at 371C in a humidified 5% CO 2 atmosphere for 24 h. Cells both suspended in the media and attached to the plates were then harvested and exposed to 0.4% Trypan blue and counted under a light microscope.
Cell cycle analysis
Cells were suspended in serum-free media containing 0.1% ethanol, 20 mM succinate, or VES (5 Â 10 5 cells/ml medium). Cells were seeded and allowed to attach for 24 h. Cells both suspended in the media and attached to the plates were then harvested. At least 1 Â 10 6 cells were fixed in 70% ethanol at 41C. After 12 h, cells were centrifuged (1000 g, 7 min, 41C), resuspended in PBS containing 0.05 mg/ml RNase A (Sigma), and then incubated at room temperature for 30 min. After washing, cells were stained with 10 mg/ml propidium iodide, filtered through a 60 mm mesh, and analysed by flow cytometry (FACS Calibur, BD Biosciences). In total, 10 000 cells were analysed with MODFIT software (Verity Software House, Inc.) (Hu et al., 2002; Ni et al., 2003) .
Cell adhesion assay
Cells were suspended in serum-free media containing 0.1% ethanol, 20 mM succinate, or VES. The cell suspensions (2.5 Â 10 5 in 0.5 ml medium/well) were added to microculture wells precoated with Matrigel (BD Biosciences). The cultures were incubated at 371C for 60 min. The wells were washed four times with PBS to remove unattached cells and then the attached cells were stained with 0.5% Crystal Violet in 20% methanol for 30 min. After washing with water, the stained cells were lysed with 30% acetic acid and the absorbance of the lysates was measured at 590 nm (Nagakawa et al., 1998) .
Cell motility assay
Cells were seeded into BioCoat Control Cell Culture Inserts (BD Biosciences) on membrane filters that were not coated with Matrigel in the presence of FCM in the bottom chamber. Migration was measured as described in the invasion assay.
Zymography
Cells seeded on 100-mm dishes were serum starved at subconfluence and treated for 24 h with different agents. The conditioned media were collected, normalized to cell number, and 20-fold concentrated using spin columns (Amicon, Beverly, MA, USA). Media (30 ml) were mixed 2 : 1 with sample loading buffer (0.25 M Tris-HCl/pH 6.8, 10% SDS, 4% sucrose, and 0.1% bromphenol blue). Samples were loaded on 4% acrylamide stacking gels and were electrophoresed (120 V) at 41C on 10% acrylamide-resolving gels containing 0.1% gelatin. After electrophoresis, the gels were soaked in 2.5% Triton X-100 on a shaker for 3 h, changing the solution every hour, to eliminate the SDS. After overnight incubation in zymogen activation buffer (50 mM Tris/pH 7.5, 200 mM NaCl, 5 mM CaCl 2 , 0.02% Brij-35) at 371C, the gels were stained with 0.5% Coomassie blue G-250 in 30% methanol/10% acetic acid for 4 h and then destained with 30% methanol/10% acetic acid, after which clear bands of digested gelatin were clearly visible (Herron et al., 1986) .
MMP-9 ELISA
Cells were suspended in serum-free media containing 0.1% ethanol or 20 mM VES. Cells were seeded in 24-well plates (2.5 Â 10 5 in 0.5 ml medium/well). The plates were incubated at 371C in a humidified 5% CO 2 atmosphere for 24 h. The levels of MMP-9 present in the conditioned medium were measured by ELISA using MMP-9 BIOTRAKTM assay kit (Amersham Pharmacia Bioteh, Piscataway, NJ, USA).
Reverse zymography
Reverse zymography was performed to detect the antiprotease activity of endogenous inhibitors of MMPs, TIMP-1 and TIMP-2, secreted into the conditioned medium. Briefly, 30 ml of 20-fold concentrated conditioned media were fractionated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). A 15% acrylamide-resolving gel containing 1 mg/ml gelatin and 160 ng/ml pro-gelatinase B was used. After electrophoresis, gels were processed as described above in zymography. Areas of the gels containing TIMPs are visualized as blue staining regions against a clear background (Herron et al., 1986) .
Real-time PCR assay
Total RNA was extracted and purified using Trizol (Invitrogen, Carlsbad, CA, USA), according to the manufacturer's instructions. First-strand complementary DNA (cDNA) was synthesized from 5 mg of DNA-free total RNA in 20 ml of reverse transcription (RT) reaction solution with a SuperScript II first-strand synthesis kit (Invitrogen). After the RT reaction, the RT product was diluted to 200 ml and the quantitative realtime PCR was performed. Briefly, the human MMP-9 specific primer pairs 5 0 -TGACAGCGACAAGAAGTG-3 0 (5 0 primer), 5 0 -CAGTGAAGCGGTACATAGG-3 0 (3 0 primer) or b-actin primer pairs 5 0 -TGTGCCCATCTACGAGGGGTATGC-3 0 (5 0 primer), 5 0 -GGTACATGGTGGTGCCGCCAGACA-3 0 (3 0 primer) were used for real-time PCR amplification. The real-time PCR was performed with 4 ml of RT product, 2 Â SYBR Green PCR Master Mix, and 0.5 ml of each primer (10 mM), in a total volume of 25 ml. PCR was performed at 951C for 3 min, and 40 cycles at 951C for 30 s, 601C for 30 s, and 721C for 30 s on an iCycler iQ Multi-color Real-time PCR detection system (Biorad, Hercules, CA, USA). Each sample was run in triplicate and data were analysed using an iCycler iQ software (Biorad, Hercules, CA, USA).
Statistical analysis
Each experiment was carried out in triplicate and repeated at least three times. Comparisons between the test group and controls in this study were evaluated using Student's t-test.
Abbreviations ECM, extracellular matrix; ELISA, enzyme-linked immunoadsorbent assay; FBS, fetal bovine serum; FCM, fibroblasts conditioned medium; MMP, matrix metalloproteinase; PCR, polymerase chain reaction; RT, reverse transcription; s.d., standard deviation; SDS-PAGE, sodium dodecyl sulfate polyacrylamide gel electrophoresis; TIMP, tissue inhibitor of matrix metalloproteinase; a-VE, a-vitamin E (RRR-a-tocopherol); VEA, a-vitamin E acetate (RRR-a-tocopheryl acetate); VES, a-vitamin E succinate (RRR-a-tocopheryl succinate).
